🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

While the benefits of GLP-1s are clear, the root of the problem is cost. It’s economically impossible to provide coverage for everyone in need without hiking rates or putting health plans at risk of bankruptcy. Thanks, NBC News & Berkeley Lovelace Jr. for including my thoughts.

"If you’re trying to lose weight, alcohol won’t help." I spoke with Parade Mag about #Ozempic & alcohol. While technically you can combine the two, I always remind my patients to consider their overall goals. bit.ly/3XR9Qag

Great to be back on Morning in America discussing GLP-1 shortages & surge of compounded versions of drugs like Ozempic & Mounjaro - their safety, efficacy, longevity as a treatment plan, & more. As far as compounded medications go, this is the Wild West. 🎥 bit.ly/4eFbPWp

21th live case ❗️❗️ 💻 Live endoscopic evaluation of the stomach after body and fundus gastric mucosa ablation 💻 Christopher McGowan, MD 🇺🇸🇺🇸🇺🇸 🗓️Let’s see the result after 15 weeks

Engaging speaking starts with the prep work, no matter your field. As a medical professional, being prepared and knowledgeable is crucial—not just for public speaking, but with every patient interaction. Excited to share my latest Forbes Business Council feature.

Lose weight or build muscle first? I recently spoke with Hone Health | The Leading Men’s TRT Provider about the common dilemma in weight management. Both approaches offer health &longevity benefits. The problem is that many weight-loss methods come at the expense of muscle. bit.ly/40Mtk33

Big news in obesity medicine: Eli Lilly’s #zepbound (tirzepatide) achieved greater weight loss compared to Novo Nordisk’s #wegovy (semaglutide). Thanks, NBC News & Berkeley Lovelace Jr. for sharing my thoughts on the trial.

I recently spoke with Medical News Today about the link between GLP-1 medications & muscle loss, who is most at risk, & the strategies to preserve muscle mass. Integrating strength training, prioritizing protein, & consistency are key to long-term success. bit.ly/3ZlupN3

Thanks, TODAY & A. Pawlowski, for sharing my insights. As an obesity physician, my main concern is patients stopping treatment—these medications are meant to be used one way and one way only: continuously.

Navigating the holidays can feel strange for patients taking #GLP1s, but pausing treatment isn't the answer. “Instead of interrupting treatment to overindulge, let’s find ways to indulge in a healthy way.” Thanks, TODAY & A. Pawlowski for featuring my insights!

I recently shared with Health why winter can make weight loss so challenging and how to combat the factors at play. "The combination of increased calorie intake and decreased movement creates a 'perfect storm' for weight gain." bit.ly/41N5qVy

Great to be back on @NewsNationAM with Hena Doba, kicking off the year discussing all things weight loss — sticking to resolutions, the obesity crisis, medical weight loss, and my "Ins" & "Outs" for 2025. Watch the full conversation here: bit.ly/425utnc

Ozempic "microdosing" is a growing trend among patients trying to cut costs or reduce side effects. While it may seem harmless, it’s entirely off-label, with no supporting clinical studies. Thanks Fox News for sharing my thoughts in the topic. bit.ly/40qqtMA

As an early & vocal advocate for #GLP1 treatments, I’ve seen firsthand their potential—and pitfalls. While highly effective when used properly, I’m increasingly concerned about their current use patterns. Here’s why: bit.ly/40Wbcnb MedPage Today   Genevieve Friedman

Had a great time on Morning in America with Hena Doba, discussing major health news beyond weight loss—including the #tuberculosis outbreak, the new FDA-approved non-opioid pain medication (#Journavx), and a test predicting #coloncancer with 90% accuracy in UC patients.

Honored to teach at the Mexico Endoscopic Bariatric Summit for the launch of #ESG & #TORe! Inspired by the skill and dedication of every physician and excited for the patients who will benefit. Thanks to Boston Scientific for an outstanding event!

Great to be back on American Glutton Podcast with Ethan Suplee! In this brand-new episode, we dive into the latest weight loss science, #GLP1 concerns, rapid weight cycling, hunger, & fundus ablation—an endoscopic technique to reduce ghrelin. Had a lot to unpack! bit.ly/4h5uuLI

A promising advancement in diabetes & obesity care from Eli Lilly and Company. “Some patients are hesitant to start an injectable therapy, no matter how effective it is. Having a pill as an option could reduce that barrier." Thanks NBC News, for including my perspective.

New data show semaglutide may reduce liver inflammation and fibrosis in MASH—a serious, progressive form of fatty liver disease. As I shared with NBC News, this is a promising step forward in addressing a common, often silent disease with limited treatment options.

I spoke with NBC News about how chronic stress impacts metabolism, sleep, and appetite, and what we can do to counteract its effects. “Replacing stress eating with even short bursts of physical activity can be a powerful shift toward long-term well-being.”